ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announced today that Dr.
Robert Rohwer, Pathogen Removal and Diagnostics Technology Inc.'s ("PRDT")
academic co-founder and Dr. Patrick Gurgel, ProMetic's Senior Research Scientist
will present at the American Chemical Society's ("ACS") 235th National Meeting
in New Orleans from April 6 - 10, 2008. Drs Rohwer and Gurgel will be speaking
during the symposium honoring Dr. Ruben Carbonell's nomination as Fellow of the
Industrial and Engineering Chemistry ("I&EC") Division of the ACS.


Dr. Carbonell is an academic co-founder of PRDT, a ProMetic joint venture with
the American Red Cross, along with Dr. Robert Rohwer.


Dr. Rohwer will be speaking on April 7, 2008 at 16:25 (EDT) and the title of his
presentation is "Managing the risks from blood-associated TSE infectivity with
prion affinity ligands".


Dr. Gurgel's lecture titled "Development of a device for prion reduction based
on affinity ligand" will be presented on April 8, 2008 at 13:30 (EDT)


The accompanying presentations will be available on ProMetic's website at
http://www.prometic.com/en/scientific_information_et.htm following the
respective lecture.


About PRDT Academic co-founders

Dr. Ruben Carbonell, is the Frank Hawkins Kenan Distinguished Professor of
Chemical and Biomolecular Engineering, and Director of the Golden LEAF
Biomanufacturing Training and Education Center ("BTEC") at North Carolina State
University. Dr. Carbonell's recent research in bioseparations led to the
identification of a specific ligand for the prion protein responsible for the
transmission of mad cow disease in humans. This ligand is being used to remove
prion protein from blood products. Dr. Carbonell is the recipient of a number of
teaching and research awards, including NC State's Alumni Distinguished Graduate
Professorship and the Alexander Quarles Holladay Medal. Dr. Carbonell joined the
faculty at NC State as a full professor in 1984. He served as head of the
Department of Chemical Engineering from 1994 to 1999. Dr. Carbonell also directs
the William R. Kenan, Jr. Institute for Engineering, Technology and Science and
is a fellow of the American Institute of Chemical Engineers and the Industrial
and Engineering Chemistry Division of the American Chemical Society.


Dr. Robert G. Rohwer is the Director of the Molecular Neurovirology Laboratory,
Veteran's Affairs Medical Center and Associate Professor of Neurology, at the
University of Maryland School of Medicine. For 30 years Dr. Rohwer has conducted
research on transmissible spongiform encephalopathies ("TSEs"), a class of fatal
neurodegenerative diseases that include Creutzfeldt-Jakob disease, which infects
humans, scrapie, which infects sheep and goats, and Bovine Spongiform
Encephalopathy ("BSE"), a newly emergent disease that affects both cattle and
humans. Dr. Rohwer's studies on the kinetics of inactivation of the TSE agents
have provided the scientific foundation for disinfection guidelines in the U.S.
and worldwide. More recently Dr. Rohwer and his laboratory team have conducted
critical experiments establishing the level, distribution and transmissibility
of TSE infectivity in blood, the results of which have been used to shape
government policies on TSE risk management around the world. Dr. Rohwer consults
on the management of TSE risks for the World Health Organization, the European
Commission, Health Canada, the U.S. Food and Drug Administration, the American
Red Cross, the U.S. Department of Agriculture and numerous commercial clients in
the biotechnology, pharmaceutical, agribusiness and related industries,
including ProMetic Life Sciences Inc.


About Pathogen Removal and Diagnostic Technologies Inc.

Pathogen Removal and Diagnostic Technologies Inc. ("PRDT") is a joint venture
established in April 2002 by The American Red Cross and ProMetic Life Sciences
Inc., and allows for the exchange of technology and knowledge between the two
organizations. PRDT's main goal is to develop products and devices to remove and
detect different pathogens from biological sources. This research augments work
that ProMetic, the American Red Cross and PRDT's scientific founders have been
conducting independently for many years.


About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical company
specialized in the research, development, manufacture and marketing of a variety
of commercial applications derived from its proprietary Mimetic Ligand(TM)
technology. This technology is used in large-scale purification of biologics and
the elimination of pathogens. ProMetic is also active in therapeutic drug
development with the mission to bring to market effective, innovative, lower
cost, less toxic products for the treatment of hematology and cancer. Its drug
discovery platform is focused on replacing complex, expensive proteins with
synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada),
ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing
facilities in the U.K. and business development activities in the U.S., Europe,
Asia and in the Middle-East.


Forward Looking Statements

This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect
our business, or if our estimates or assumptions turn out to be inaccurate. Such
risks and assumptions include, but are not limited to, ProMetic's ability to
develop, manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of ProMetic to
take advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in economic
conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current
expectations on page 21 of ProMetic's Annual Information Form for the year ended
December 31, 2007, under the heading "Risk Factors". As a result, we cannot
guarantee that any forward-looking statement will materialize. We assume no
obligation to update any forward-looking statement even if new information
becomes available, as a result of future events or for any other reason, unless
required by applicable securities laws and regulations.
Archon Minerals (TSXV:ACS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Archon Minerals Charts.
Archon Minerals (TSXV:ACS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Archon Minerals Charts.